Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company developing treatments for severe bacterial and fungal infections, has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant will support initial preclinical activities on the antibiotics program recently acquired from Spexis. The initial funding of up to $0...